An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML
S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier
This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.
bioRxiv · Dec 28, 2020Cancer Biology